Preclinical screen demonstrates that mitophagy drives resistance to BH3 mimetics in acute myeloid leukemia cells, indicating targeting MFN2 or MARCH5 restores sensitivity.
Supplemental Figure S1 shows the integration of CRISPR/Cas9 loss-of-function screens to identify dependencies and liabilities in BH3-mimetics treatments. Supplemental Figure S2 demonstrates that increased mitochondria-ER interactions contribute to BH3-mimetics resistance. Supplemental Figure S3 shows that mitophagy affects the responsiveness of AML cells to BH3-mimetics. Supplemental Figure S4 reveals that enhanced autophagic clearance of mitochondria as a mechanism of resistance to BH3-mimetics in AML. Supplemental Figure S5 exhibits the synergism between BH3-mimetics and macroautophagy inhibition in human AML. Supplemental Figure S6 shows that deletion of MFN2 or MARCH5 sensitizes AML cells to BH3-mimetics. Supplemental Figure S7 displays that targeting of MFN2 or MARCH5 impairs the process of mitophagy.
No takes yet. Share an insight, caveat, or question.
Glytsou et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: